Lithium Versus Other Mood-Stabilizing Medications in a Longitudinal Study of Youth Diagnosed With Bipolar Disorder
Lithium Versus Other Mood-Stabilizing Medications in a Longitudinal Study of Youth Diagnosed With Bipolar Disorder
复制标题
DOI：
10.1016/j.jaac.2019.06.013
复制
发表时间：
2020-10-01
影响因子：
13.3
通讯作者：
Birmaher, Boris
中科院分区：
文献类型：
--
作者：
Hafeman, Danella M.;Rooks, Brian;Birmaher, Boris
目的：锂是成人双相情感障碍（BD）治疗的主要药物，但在青年中的证据有限。我们使用的数据从过程和双相青年（COBY）的研究结果，以评估是否锂与其他情绪稳定药物（OMS）与改善的结果，包括情绪症状和suicidality.Method：COBY是一个自然的，纵向研究413青年，7至17.11岁的摄入量，与BD。在每次访视时，使用青少年纵向间隔随访评价评估前一随访期的药物暴露、精神症状和心理社会功能。使用混合模型，我们确定是否参与者服用锂与OMS（但不是锂）不同的情绪症状，自杀，心理社会功能，住院，侵略，和substance use.Results：共340名参与者贡献了2,638个六个月的随访期（886锂，1,752 OMS），平均随访10年。在锂（与OMS）随访期间，参与者年龄较大，不太可能有终身焦虑，也不太可能服用抗抑郁药（p值
Objective: Lithium is the mainstay for bipolar disorder (BD) treatment in adults, but evidence in youths is limited. We used data from the Course and Outcome of Bipolar Youth (COBY) study to assess whether lithium vs other mood-stabilizing medication (OMS) was associated with improved outcomes, including mood symptoms and suicidality.Method: COBY is a naturalistic, longitudinal study of 413 youths, 7 to 17.11 years old at intake, with BD. At each visit, medication exposure, psychiatric symptoms, and psychosocial function over the preceding follow-up period were assessed using the Adolescent Longitudinal Interval Follow-Up Evaluation. Using mixed models, we determined whether participants taking lithium vs OMS (but not lithium) differed regarding mood symptoms, suicidality, psychosocial function, hospitalization, aggression, and substance use.Results: A total of 340 participants contributed 2,638 six-month follow-up periods (886 lithium, 1,752 OMS), over a mean follow-up of 10 years. During lithium (vs OMS) follow-up periods, participants were older, less likely to have lifetime anxiety, and less likely to be on antidepressants (p values